MTVA 8-K: SEC filing
MetaVia Inc.
Filed with the SEC on · accession 0001104659-26-128856
MTVA filed a 8-K (current report) with the SEC on Nov 17, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
MetaVia Inc. announced that the last patient has completed the final study visit in its Phase 1 clinical trial of DA-1726, a novel GLP-1/glucagon dual-receptor agonist.
Key details
✦ Ask GOAX AI about this filing — what it means for MTVA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MTVA?
Click hereFrequently asked questions
What did MTVA file with the SEC on Nov 17, 2026?
MTVA filed a 8-K (SEC filing). MetaVia Inc. announced that the last patient has completed the final study visit in its Phase 1 clinical trial of DA-1726, a novel GLP-1/glucagon dual-receptor agonist.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other MTVA SEC filings
Get alerts when MTVA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days